In compliance with current legislation and regulations, Ulisse BioMed has approved an internal dealing procedure aimed at ensuring transparency with regard to significant transactions involving the purchase or sale of company shares held, directly or indirectly, by persons who are able to influence company decisions or who are in possession of information that could affect the performance of the stock on the markets.

This section contains communications and notifications received from Relevant Parties, as defined in the procedure.

Download the template for notification and public disclosure of transactions carried out by persons performing administrative, supervisory or management functions and by persons closely associated with them.